Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
Most importantly, neither agent has raised major red flags in terms of serious adverse events in the trials conducted to date
Key Factors Influencing the Onset Speed of Dihexa 1.Route of Administration Injection or sublingual administration allows Dihexa to bypass first-pass metabolism and enter the bloodstream more rapidly, though these routes carry higher risks
The use of human keratinocytes and human skin models for predicting skin irritation
